Characterization of TNG348: a selective, allosteric USP1 inhibitor that synergizes with PARP inhibitors in tumors with homologous recombination deficiency.
Simoneau A, Pratt CB, Wu HJ, Rajeswaran SS, Comer CG, Sudsakorn S, Zhang W, Liu S, Meier SR, Choi AH, Khendu T, Stowe H, Shen B, Whittington DA, Chen Y, Yu Y, Mallender WD, Feng T, Andersen JN, Maxwell JP, Throner S.
Simoneau A, et al. Among authors: feng t.
Mol Cancer Ther. 2025 Jan 31. doi: 10.1158/1535-7163.MCT-24-0515. Online ahead of print.
Mol Cancer Ther. 2025.
PMID: 39886906